- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Biocon Limited — Important, 29-07-2026: Updates
29-07-2026 | 08:31 am
29-07-2026 | 08:31 am
Biocon's Canadian subsidiary secured Health Canada approval for Yesintek® (ustekinumab) Autoinjector Pen. This new format strengthens Biocon's immunology portfolio in Canada, providing a unique patient option for autoimmune conditions like psoriasis and Crohn's disease, boosting market access.
No comments yet. Be the first to comment!